12:00 AM
Sep 20, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hybrid Capture II human papillomavirus: Marketed as an adjunct to the Pap smear for cervical cancer screening

Researchers published data from 2,988 patients in the British Journal of Cancer showing 95 percent sensitivity in detecting high-grade cervical lesions...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >